Gensia Inc substantially reduces loss in 1995

11 March 1996

- Gensia Inc substantially reduced its loss in 1995 to $11.9 million or 36 cents from $56.1 million or $1.89 a year earlier. This was due to receipt of $55.4 million in one-time revenues and a reduction of $22.4 million in R&D expenses. Total revenues in 1995 were $122 million, up 69.9%.

For the fourth quarter of 1995, revenues at Gensia amounted to $72.5 million, which included one-time revenues of $55.4 million. Net income for the quarter amounted to $24.3 million or 71 cents, compared to a loss recorded in fourth quarter 1994 of $5.1 million or 16 cents.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight